No COVID-19 vaccine is ready worldwide—not even in China. Yet, as the country advances multiple candidates through testing, it's already constructing high-security labs to ramp up production. Officials project needs in the hundreds of millions of doses annually, with several advanced facilities now complete.
As the global COVID-19 death toll surpassed 400,000, researchers worldwide race for a vaccine. Chinese teams are targeting rollout within months. While no vaccine is finalized, secure production laboratories are already built to meet biosafety standards.
A May 31, 2020, South China Morning Post report details five vaccines in testing, four as "inactivated vaccines" that neutralize the virus to trigger immunity without causing illness. These require stringent biosafety, classifying the labs at Level 3—the second-highest standard.
Phase 2 trials are slated to wrap by late July, but Phase 3 demands thousands of volunteers for injection. With COVID-19 contained domestically, Chinese authorities are pushing trials forward aggressively.
In record time—echoing the 10-day Wuhan hospital built amid the outbreak—China has finished two production units. Led by Sinopharm (China National Pharmaceutical Group), these Beijing and Wuhan facilities boast annual capacities of 100 million and 80 million doses, respectively. More sites may follow.
These labs will address priority demands from "special population groups," including healthcare workers, diplomats, overseas students, and Belt and Road project staff. Notably, officials signal vaccinations for select groups by year-end, even before trials conclude.
